Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes
Pharmaceutical Research · 2026
DOI: 10.1007/s11095-026-04056-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2026. Verfasst von Behnaz Dolatabadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, ShK.C., Islamic Azad University, Shahrekord, Iran. Hauptthemen laut MEDLINE: Lapatinib, Breast Neoplasms, Metal Nanoparticles, Silver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lapatinib is a dual EGFR/HER2 tyrosine kinase inhibitor used in HER2-positive breast cancer (BC). Here, we identified prognostic genes modulated by lapatinib and evaluated whether glucose-functionalized, lapatinib-conjugated silver nanoparticles could enhance its anticancer efficacy. METHODS: Lapatinib-responsive genes were identified from the GSE38376 dataset and their prognostic associations were assessed using The Cancer Genome Atlas (TCGA). Silver nanoparticles were synthesized by Spirulina-mediated reduction of AgNO₃, functionalized with glucose, and conjugated to lapatinib (Ag@Glu-Lapatinib NP), then characterized by FTIR, XRD, zeta potential, SEM, and TEM. SKBR3 cells were treated with Ag@Glu-Lapatinib NP, Ag NP, or lapatinib and evaluated by MTT, Annexin V/PI apoptosis assay, and RT-qPCR for candidate genes. RESULTS: Transcriptomic analysis indicated that lapatinib suppresses proliferation-associated genes and enriches apoptosis-related pathways. In TCGA, ECE2 and CDCA5 were overexpressed and associated with poorer outcomes, whereas PDK4 and ALDH1A1 were reduced and linked to favorable prognosis. Ag@Glu-Lapatinib NP formation was confirmed, and the nanoformulation showed higher potency (IC₅₀ = 62 μg/mL at 24 h; 31 μg/mL at 48 h) than free lapatinib (250 μg/mL) or Ag NP (125 μg/mL), with markedly increased apoptosis. RT-qPCR verified significant modulation of ECE2, CDCA5, PDK4, and ALDH1A1 after Ag@Glu-Lapatinib NP treatment. CONCLUSION: Conjugating lapatinib to glucose-functionalized silver nanoparticles enhances its activity in HER2-positive BC cells and modulates survival-associated genes. This nano-therapeutic strategy may strengthen the therapeutic potential of lapatinib in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, ShK.C., Islamic Azad University, Shahrekord, Iran.
- Department of Biology, ShK.C., Islamic Azad University, Shahrekord, Iran. m.peymani@iau.ac.ir.
- Department of Genetics, TeMs.C., Islamic Azad University, Tehran, Iran. mhashemi@iau.ac.ir.
- Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. mhashemi@iau.ac.ir.
- Department of Biology, Ra.C., Islamic Azad University, Rasht, Iran.
- Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, 34396, Istanbul, Türkiye.
Zitieren
APA
Dolatabadi, B., Peymani, M., Hashemi, M., Rouhi, L., Salehzadeh, A., & Zarrabi, A. (2026). Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes. Pharmaceutical Research. https://doi.org/10.1007/s11095-026-04056-w
Vancouver
Dolatabadi B, Peymani M, Hashemi M, Rouhi L, Salehzadeh A, Zarrabi A. Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes. Pharmaceutical Research. 2026. doi:10.1007/s11095-026-04056-w
BibTeX
@article{Dolatabadi2026,
author = {Dolatabadi, Behnaz and Peymani, Maryam and Hashemi, Mehrdad and Rouhi, Leila and Salehzadeh, Ali and Zarrabi, Ali},
title = {Lapatinib-Loaded Glucose-Functionalized Silver Nanoparticles Enhance Efficacy in HER2-Positive Breast Cancer Cells and Modulate Survival-Associated Genes},
journal = {Pharmaceutical Research},
year = {2026},
doi = {10.1007/s11095-026-04056-w}
}
EUVIMED